EA201892441A1 - Композиции микрорнк и способы их создания и применения - Google Patents

Композиции микрорнк и способы их создания и применения

Info

Publication number
EA201892441A1
EA201892441A1 EA201892441A EA201892441A EA201892441A1 EA 201892441 A1 EA201892441 A1 EA 201892441A1 EA 201892441 A EA201892441 A EA 201892441A EA 201892441 A EA201892441 A EA 201892441A EA 201892441 A1 EA201892441 A1 EA 201892441A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mir
seq
creation
methods
application
Prior art date
Application number
EA201892441A
Other languages
English (en)
Inventor
Стивен Джон Греко
Пранела Рамешвар
Original Assignee
ЭДВАНСД РЕГЕН МЕДИКАЛ ТЕКНОЛОДЖИ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭДВАНСД РЕГЕН МЕДИКАЛ ТЕКНОЛОДЖИ, ЭлЭлСи filed Critical ЭДВАНСД РЕГЕН МЕДИКАЛ ТЕКНОЛОДЖИ, ЭлЭлСи
Priority claimed from PCT/US2017/030117 external-priority patent/WO2017190000A1/en
Publication of EA201892441A1 publication Critical patent/EA201892441A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Abstract

Способ, включающий введение субъекту композиции, содержащей выделенную микроРНК, имеющую последовательность, выбранную из группы, состоящей из miR-19a-3p (SEQ ID NO: 1), miR-103a-3p (SEQ ID NO: 2), miR-106b-5p (SEQ ID NO: 3), miR-146a-5p (SEQ ID NO: 4), miR-223-5p (SEQ ID NO: 5), miR-4497 (SEQ ID NO: 6), miR-1303 (SEQ ID NO: 7), miR-619-5p (SEQ ID NO: 8), miR-1273f (SEQ ID NO: 9), miR-7851-3p (SEQ ID NO: 10), их функционального варианта и их комбинаций.
EA201892441A 2017-04-06 2017-04-28 Композиции микрорнк и способы их создания и применения EA201892441A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762482465P 2017-04-06 2017-04-06
PCT/US2017/030117 WO2017190000A1 (en) 2016-04-29 2017-04-28 Microrna compositions and methods of making and using same

Publications (1)

Publication Number Publication Date
EA201892441A1 true EA201892441A1 (ru) 2019-07-31

Family

ID=67399614

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892441A EA201892441A1 (ru) 2017-04-06 2017-04-28 Композиции микрорнк и способы их создания и применения

Country Status (1)

Country Link
EA (1) EA201892441A1 (ru)

Similar Documents

Publication Publication Date Title
PH12021500014A1 (en) Fused ring compounds
PH12021551065A1 (en) Fused ring compounds
MX2019009861A (es) Composiciones farmaceuticas de un derivado de acido biliar y microbioma y usos de las mismas.
BR112017022349A2 (pt) ?composto, composição, método, e, método para inibir uma proteína irak?
PH12020550051A1 (en) Glp-1 compositions and uses thereof
DOP2016000051A (es) Polipéptido para la escisión hidrolítica de la zearalenona y/o derivados de la zearalenona, polinucleótido aislado de la misma y poliéptido que contiene aditivo, uso y procedimiento de los mismos.
EA201691794A1 (ru) Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
EA201992610A1 (ru) Экспансия -t-клеток, композиции и способы их применения
MY195442A (en) Anti-CD40 Antibodies and Their Uses
BR112018072198A2 (pt) composição compreendendo micrornas, método de preparação de uma composição de célula-tronco restaurada, formulação farmacêutica e kit
EA201592263A1 (ru) Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования
EA201890572A1 (ru) Биофармацевтические композиции
EA202090720A1 (ru) ПРОИЗВОДНЫЕ GalNAc
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
JOP20200323A1 (ar) طرق لتصنيع تركيبات الأحماض الأمينية
MX2016014144A (es) Composiciones de proteina concentrada y metodos para su elaboracion y uso.
EA201892500A1 (ru) Применение фракции лигнина в качестве антифитопатогенного агента и содержащие ее антифитопатогенные композиции
MX2020008125A (es) Composiciones que comprenden berberina.
MX2020007945A (es) Proteinas f del rsv estabilizadas y usos de las mismas.
EA202092695A1 (ru) Композиции, содержащие глюкозу и гемицеллюлозу, и их применение
PH12021551100A1 (en) Dried biological compositions and methods thereof
WO2018097603A3 (ko) 중동호흡기증후군 코로나바이러스 s 단백질 면역원 조성물 및 이의 제작 방법
EA201990998A1 (ru) Фармацевтические составы и способы их получения
EA201790415A1 (ru) ЛИОФИЛИЗИРОВАННЫЕ СОСТАВЫ ДЛЯ АНТИДОТА ФАКТОРА Xa
WO2015107363A3 (en) Mycobacterial antigen composition